Work

S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.3_suppl.tps790

Authors: Scott Kopetz, Shannon McDonough, Van Karlyle Morris, Heinz-Josef Lenz, Anthony M. Magliocco, Chloe Evelyn Atreya, Luis A. Diaz, Carmen Joseph Allegra, Christopher Hanyoung Lieu, S. Gail Eckhardt, Thomas John Semrad, Kimberly Kaberle, Katherine Guthrie, Howard S. Hochster

Institutions: The University of Texas MD Anderson Cancer Center, USC Norris Comprehensive Cancer Center, Moffitt Cancer Center, University of California, San Francisco, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Florida, University of Colorado Denver, University of Colorado Anschutz, UC Davis Comprehensive Cancer Center, SWOG Cancer Research Network, Fred Hutch Cancer Center, Yale University

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2292073775

Cites:

Cited by: 7

Related to: 10